12-month effect of middle ear pressure therapy with the EFET01 device for intractable definite Meniere’s disease and delayed endolymphatic hydrops after certification by the public health insurance system in Japan
12-month effect of middle ear pressure therapy with the EFET01 device for intractable definite Meniere’s disease and delayed endolymphatic hydrops after certification by the public health insurance system in Japan
复制标题
日本公共健康保险系统认证后，使用 EFET01 装置进行中耳压力治疗顽固性梅尼埃病和迟发性内淋巴积水的 12 个月效果
DOI：
10.1080/00016489.2022.2085325
复制
发表时间：
2022
影响因子：
1.4
通讯作者：
Shojaku Hideo
中科院分区：
文献类型：
--
作者：
Nakazato Akira;Takakura Hiromasa;Ueda Naoko;Do Tram Anh;Takeda Noriaki;Watanabe Yukio;Shojaku Hideo
中耳压迫疗法(MEPT)对确诊梅尼埃病(MD)和难治性迟发性内淋巴积水(DEH)患者的顽固性眩晕有效。EFET01®是日本开发的一种MEPT设备，自2018年9月起纳入国家医疗保险，为期四个月的MEPT已显示出疗效。然而，治疗12个月后的有效性和安全性尚不清楚，这适合于确定 装置的疗效。目的检验使用ETET01®的12个月MEPT的疗效。33例随访12个 月的患者参加了这项回顾性研究。在第1个疗程和第2个6个月疗程中对临床数据进行评估。第二个6个月的数据与使用不同设备的MEPT研究的数据进行比较。结果使用EFET01®的MEPT在第一个阶段显著改善眩晕，第二个阶段进一步改善。结论MEPT配合EFET01®治疗MD和DEH明确的顽固性眩晕是有效的，建议随访12个月。
BackgroundMiddle ear pressure therapy (MEPT) is effective for intractable vertigo in patients with definite Meniere’s disease (MD) and treatment-refractory delayed endolymphatic hydrops (DEH). Four-month MEPT with the EFET01®, an MEPT device developed in Japan and covered by national health insurance since September 2018, has shown efficacy. However, efficacy and safety after 12 months of treatment, which is appropriate for determining the therapeutic effect of MEPT devices, is unclear.ObjectivesExamine the therapeutic effect of 12-month MEPT using the ETET01®.Material and MethodsPatients underwent MEPT using the EFET01®from September 2018 to July 2021. Thirty-three patients followed for >12 months were enrolled in this retrospective study. Clinical data were evaluated in the first and second 6-month treatment periods. Data from the second 6-month period were compared with data from an MEPT study using a different device.ResultsMEPT with the EFET01®significantly improved vertigo in the first period, with further improvement in the second period. The efficacy and safety were comparable to MEPT with other devices.ConclusionsMEPT with the EFET01®is effective for intractable vertigo in patients with definite MD and DEH, and 12-month follow-up is recommended.SignificanceThe efficacy of 12-month MEPT with the EFET01®was demonstrated.
登录
查看更多内容
使用中耳压力应用控制梅尼埃病患者的症状：两年随访
影响因子：
1.4
作者：
K. Sass;B. Densert
通讯作者：
B. Densert
DOI：
10.1152/ajprenal.1996.270.6.f1073
发表时间：
1996
期刊：
The American journal of physiology
影响因子：
--
作者：
K. Qvortrup;J. Rostgaard;N. Holstein
通讯作者：
N. Holstein
梅尼埃病。
DOI：
10.1007/bf00168023
发表时间：
1995
期刊：
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
影响因子：
--
作者：
Merchant,SN;Rauch,SD;NadolJr,JB
通讯作者：
NadolJr,JB
使用压力室立即恢复基础感音神经性听力（Mb Meniere）。
影响因子：
1.4
作者：
O. Densert;S. Ingelstedt;A. Ivarsson;K. Pedersen
通讯作者：
K. Pedersen
影响因子：
1.8
作者：
Fukushima M;Akahani S;Inohara H;Takeda N
通讯作者：
Takeda N